{"timestamp": "2026-01-18T17:40:40.601463", "question": "{}", "final_output": "Final Assessment:\nDisseminated recurrent gynecologic malignancy with progressive pelvic, liver, and probable bone involvement in a non‑curative setting; histologic subtype, primary site, performance status, and anemia etiology remain unresolved. [@2022-12-29|MR; @2022-12-29|CT; @20230103|5600862]\n\nCore Treatment Strategy:\n- Maintain non‑curative, symptom‑focused intent and engage palliative care for pain, bowel/bladder, and liver/bone symptom management.  \n- Urgently evaluate severe anemia (iron/B12/folate, bleeding/hemolysis) and provide transfusion/supportive care before systemic therapy decisions. [@20230103|5600862]  \n- Expedite retrieval/review of all pathology (initial and recurrence histology, IHC, staging) and full prior treatment history; currently unknown.  \n- Defer new systemic treatment intensity and any radiotherapy planning until anemia work‑up, ECOG status, pathology clarification, and patient goals are documented.  \n\nChange Triggers:\n- If anemia stabilized and ECOG acceptable, then revisit suitability and goals of systemic therapy versus best supportive care focus.  \n- If pathology/treatment history clarify primary site and subtype, then individualize systemic and radiotherapy strategies per disease biology and prior exposure.", "initial_ops": {"chair": "- Advanced recurrent pelvic malignancy with progressive sacral, peritoneal, bone and liver metastases; intent should now be non-curative, symptom-focused. [@2022-12-29|MR; @2022-12-29|CT; @2022-10-24|CT]\n\n- Marked anemia (Hgb 74 g/L) requires urgent evaluation, transfusion consideration and cause clarification before systemic therapy decisions. [@20230103|5600862]\n\n- Liver and renal function currently acceptable, permitting consideration of further systemic therapy if performance status and symptoms allow. [@20221229|8300002]\n\n- Germline HRD-negative, BRCA wild type with ATM variant; PARP benefit uncertain, prioritize conventional systemic options or trials. [@OH2203828|2022-04-18]\n\n- Critical missing data: histology/grade, initial stage, prior treatments and responses, current ECOG, symptoms, and patient preferences/goals.", "oncologist": "- Tumor markers CA125, CA19-9, CA15-3 markedly elevated, supporting active gynecologic malignancy; histologic diagnosis and stage unknown/needs update. [@20221229|9703212]\n\n- Severe anemia (Hgb 74 g/L) likely limits intensity of cytotoxic therapy; etiology and transfusion/iron status unknown/needs update. [@20230103|5600862]\n\n- Renal and hepatic function acceptable for most systemic agents, but full panel including electrolytes and eGFR confirmation needed. [@20221229|8300002]\n\n- HRD negative, BRCA1/2 negative, germline ATM variant identified; implications for targeted therapy modest. [@OH2203828|2022-04-18]\n\n- Missing: exact cancer diagnosis, prior systemic treatments, treatment response, performance status, current disease burden/imaging to define line and intent.", "radiologist": "- Presacral pelvic mass enlarged to ~53×44 mm with more heterogeneous signal; involves adjacent peritoneum and sacrum, suggesting progressive local recurrence.[@2022-12-29|MR]\n\n- Persistent thickened vaginal stump and enhancing rectal wall segment adjacent to mass, raising concern for direct local involvement.[@2022-12-29|MR]\n\n- New enhancing nodule in right iliac bone, suspicious for osseous metastasis.[@2022-12-29|MR]\n\n- Multiple enhancing mesenteric/pelvic nodules unchanged, compatible with stable peritoneal metastatic disease.[@2022-12-29|MR]\n\n- Liver: multiple metastatic lesions increased in number and size; additional stable hepatic cysts and possible splenic infarct needing follow‑up.[@2022-12-29|CT]", "pathologist": "- No histology, grade, site, or IHC results are available; primary diagnosis cannot be confirmed or classified.  \n- Germline ATM exon8 c.A947G:p.Y316C variant reported; clinical significance (pathogenic vs VUS) not specified. [@OH2203828|2022-04-18]  \n- HRD testing reported negative; BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 pathogenic variants not detected. [@OH2203828|2022-04-18]  \n- Tumor somatic NGS panel, MSI/MMR, TMB, and PD-L1 status unknown/needs update.  \n- Full surgical pathology report (histotype, grade, stage, margins, residual disease) and IHC panel results unknown/needs update.", "nuclear": "- No prior PET/CT available; baseline metabolic characterization of pelvic, hepatic, and osseous lesions is unknown/needs PET-CT update.\n\n- MRI shows enlarging presacral mass with sacrum and peritoneal involvement, highly suspicious for local pelvic recurrence. [@2022-12-29|MR]\n\n- New right iliac bone enhancing lesion on MRI suggests possible osseous metastasis; PET could confirm metabolic activity and extent. [@2022-12-29|MR]\n\n- CT shows multiple increasing liver lesions consistent with metastases; PET may refine lesion count and confirm active disease burden. [@2022-12-29|CT]\n\n- PET/CT now would help refine staging (visceral and bone metastases vs localized recurrence) and guide future management planning."}, "merged_summary": "Key Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver metastases, and new suspected iliac bone metastasis → non‑curative intent.\n- Severe anemia (Hgb 74 g/L) is a major constraint on systemic therapy; liver/renal function currently compatible with treatment if ECOG is acceptable.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic‑type malignancy.\n- HRD negative, BRCA1/2 wild type with ATM variant of uncertain significance → limited expected benefit from PARP; conventional systemic options or trials more relevant.\n\nControversies:\n- Unconfirmed primary site and histologic subtype (ovarian vs other gynecologic/pelvic origin); original stage unclear.\n- Systemic treatment intensity and feasibility cannot be decided safely without anemia work‑up, ECOG, and documented patient goals.\n- PET/CT considered optional in a clearly metastatic, non‑curative setting; potential role only if it would influence palliative radiotherapy planning, systemic strategy, or trial eligibility.\n\nMissing Info:\n- Pathology: original and recurrence reports with histology, grade, IHC, primary site confirmation, and staging; current decisions are being made without a fully confirmed histologic diagnosis.\n- Treatment history: prior systemic and radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences and goals of care.\n- Hematology: anemia etiology, iron/B12/folate status, hemolysis/bleeding assessment, transfusion history.\n- Updated labs/biomarkers: full biochemistry including eGFR, electrolytes, LFTs; somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline to map metabolic extent of visceral and bone disease.\n\nWorking Plan:\n- Reaffirm non‑curative, symptom‑focused intent and engage palliative care for pain and pelvic/visceral symptom control.\n- Urgently complete anemia work‑up and provide transfusion/supportive measures before any decision on systemic treatment intensity.\n- Formalize that systemic therapy intensity is deferred until anemia evaluation, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, and IHC to confirm primary/site.\n- Consider PET/CT only if results are needed to guide palliative radiotherapy targeting or to meet documentation requirements for clinical trials, with radiology–nuclear correlation for bone/liver lesions.", "final_round_ops": {"Round 1": {"chair": "- Confirm non-curative, symptom-focused intent and involve palliative care for pain, pelvic, bowel, and liver-related symptom control.  \n\n- Defer systemic treatment intensity decisions until anemia work-up, ECOG, symptom burden, and patient goals are documented; provide transfusion/supportive care meanwhile. [@20230103|5600862]  \n\n- Urgently retrieve and review all original and recurrence pathology (histology, grade, IHC, primary site) plus full treatment history; current status unknown.  \n\n- Consider PET/CT only if results will change palliative radiotherapy targeting (e.g., sacrum/iliac bone/liver) or clinical trial eligibility; otherwise optional. [@2022-12-29|MR; @2022-12-29|CT]  \n\n- Plan next MDT after pathology/treatment history, anemia evaluation, ECOG, and updated labs/biomarkers are available to individualize systemic/palliative strategies.", "oncologist": "- Defer systemic treatment intensity decisions until anemia work-up, ECOG performance, symptoms, and patient goals are fully documented. [@20230103|2023-01-03]  \n\n- Urgently investigate and treat anemia (iron/B12/folate, bleeding/hemolysis, transfusion support) before any new systemic regimen. [@20230103|2023-01-03]  \n\n- Retrieve and review complete pathology (initial and recurrence histology, grade, IHC) to clarify primary site and subtype; current status unknown.  \n\n- Maintain non-curative, symptom-focused intent with early palliative care involvement for pelvic pain, bowel/bladder issues, and liver/bone symptoms.  \n\n- Consider PET/CT only if results will change palliative radiotherapy planning, systemic strategy, or clinical trial eligibility; currently optional.", "radiologist": "- Progressive presacral mass invading sacrum/peritoneum with probable vaginal stump/rectal involvement; symptomatic course likely, curative local control unrealistic.[@2022-12-29|MR]\n\n- Liver metastases increased in number and size, confirming disseminated visceral disease burden in a non‑curative context.[@2022-12-29|CT]\n\n- New right iliac bone enhancing nodule suspicious for bone metastasis; may become relevant for targeted palliative radiotherapy.[@2022-12-29|MR]\n\n- Pelvic/mesenteric peritoneal nodules stable, representing persistent peritoneal dissemination without clear radiologic obstruction currently.[@2022-12-29|MR]\n\n- PET/CT remains optional; consider only if it would alter palliative radiotherapy fields or trial eligibility via better metastatic mapping.[@2022-12-29|CT]", "pathologist": "- Systemic treatment intensity is deferred until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \n- Pathology team to urgently retrieve and review all original and recurrence specimens with full histology, grade, and IHC; primary site currently unknown.  \n- Maintain non‑curative, symptom‑focused intent; involve palliative care for pain and pelvic/visceral symptom management (clinical status details currently unknown).  \n- PET/CT is optional; consider only if it will guide targeted palliative radiotherapy planning or trial eligibility requiring precise metastatic mapping.  \n- Once anemia etiology, performance status, patient preferences, and definitive pathology are available, the oncology team will reassess systemic strategy and trial options.", "nuclear": "- Maintain non‑curative, symptom‑focused intent; involve palliative care for pelvic pain and visceral symptom management (clinical status details unknown).  \n\n- Defer systemic treatment intensity decisions until anemia work‑up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \n\n- Pathology team to urgently retrieve/review all original and recurrence specimens with full histology, grade, and IHC; current primary/site remains unconfirmed.  \n\n- PET/CT is optional; obtain only if results would change palliative radiotherapy fields, systemic strategy, or clinical trial eligibility (no prior PET/CT).  \n\n- If PET/CT performed, integrate FDG findings with CT/MR to confirm bone (right iliac) and liver metastases for radiotherapy planning. [@2022-12-29|MR; @2022-12-29|CT]"}, "Round 2": {"chair": "- Reaffirm non-curative, symptom-focused intent and engage palliative care for pain and pelvic/visceral symptom control; primary site still unknown.  \n\n- Urgently investigate anemia etiology and give transfusion/supportive care before deciding on systemic treatment intensity. [@20230103|5600862]  \n\n- Defer systemic therapy intensity until anemia work-up, ECOG, symptom burden, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \n\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, IHC, and staging; currently unknown.  \n\n- Reserve PET/CT for situations where findings would alter palliative radiotherapy fields (sacrum/iliac/liver) or clinical trial eligibility; otherwise optional.", "oncologist": "- Reaffirm non-curative, symptom-focused intent and involve palliative care early for pelvic, visceral, and potential bone symptom management; staging details unknown.  \n\n- Urgently investigate and treat severe anemia before systemic therapy decisions (iron/B12/folate, bleeding/hemolysis, transfusion as needed). [@20230103|2023-01-03]  \n\n- Defer systemic treatment intensity until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented; currently unknown.  \n\n- Pathology to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, IHC, and staging; currently unknown.  \n\n- Consider PET/CT only if findings would change palliative radiotherapy targeting, systemic strategy, or satisfy clinical trial documentation requirements; currently optional.", "radiologist": "- Presacral pelvic mass with sacral/peritoneal invasion and probable vaginal stump/rectal involvement indicates progressive, locally advanced recurrent disease.[@2022-12-29|MR]\n\n- Liver metastases have increased in number and size, confirming progression of disseminated visceral disease.[@2022-12-29|CT]\n\n- New right iliac bone enhancing nodule remains suspicious for bone metastasis and may guide future palliative radiotherapy targeting.[@2022-12-29|MR]\n\n- Pelvic/mesenteric peritoneal nodules are stable, representing persistent peritoneal dissemination without current radiologic obstruction.[@2022-12-29|MR]\n\n- PET/CT stays optional; obtain only if needed to refine radiotherapy fields or trial-required metastatic mapping.[@2022-12-29|CT]", "pathologist": "- Maintain non‑curative, symptom‑focused intent; engage palliative care for pain and pelvic/visceral symptom control (clinical details currently unknown).  \n- Defer systemic therapy intensity until anemia work‑up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \n- Pathology team to urgently retrieve/review all original and recurrence specimens with full histology, grade, IHC, and staging; primary/site currently unknown.  \n- Complete anemia evaluation (iron/B12/folate, hemolysis/bleeding, transfusion history) and provide supportive care before revisiting systemic options (lab details unknown).  \n- Use PET/CT only if needed for precise palliative radiotherapy targeting or to fulfill clinical trial metastatic documentation requirements.", "nuclear": "- Non‑curative, symptom‑focused intent remains appropriate; engage palliative care for pelvic and visceral symptom management (clinical details currently unknown).  \n\n- Defer systemic treatment intensity until anemia work‑up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \n\n- Pathology team to urgently retrieve/review all original and recurrence specimens with full histology, grade, IHC, and staging (currently unknown).  \n\n- PET/CT is optional; perform only if it will guide palliative radiotherapy targeting or clinical‑trial eligibility (no prior PET/CT available).  \n\n- If PET/CT obtained, correlate FDG‑avid bone and liver lesions with CT/MR to confirm metastases for radiotherapy planning. [@2022-12-29|MR; @2022-12-29|CT]"}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": "Before committing to further systemic therapy, please urgently clarify anemia etiology and ECOG/symptoms, and retrieve full pathology/treatment history to confirm disease classification and realistic treatment intensity.", "radiologist": null, "pathologist": null, "nuclear": "PET/CT should only be pursued if it will concretely influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting."}, "oncologist": {"chair": "Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": "PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility."}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": "Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.", "oncologist": "Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification.", "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": "Please formalize that systemic treatment intensity is deferred until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.", "radiologist": null, "pathologist": "Kindly prioritize retrieval/review of all original and recurrence pathology with full histology, grade, and IHC so that ongoing management is not based on an unconfirmed primary/site.", "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": "From a nuclear perspective, PET/CT is optional but could meaningfully refine bone and whole‑body disease mapping if you’re considering targeted palliative radiotherapy or trial screening that requires precise metastatic documentation.", "radiologist": "If PET/CT is obtained, please correlate FDG‑avid bone and liver lesions with prior CT/MR to distinguish metastases from benign/incidental findings for radiotherapy planning.", "pathologist": null, "nuclear": null}}}, "Round 2": {"Turn 1": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Advanced recurrent pelvic malignancy with progressive sacral, peritoneal, bone and liver metastases; intent should now be non-curative, symptom-focused. [@2022-12-29|MR; @2022-12-29|CT; @2022-10-24|CT]\n\n- Marked anemia (Hgb 74 g/L) requires urgent evaluation, transfusion consideration and cause clarification before systemic therapy decisions. [@20230103|5600862]\n\n- Liver and renal function currently acceptable, permitting consideration of further systemic therapy if performance status and symptoms allow. [@20221229|8300002]\n\n- Germline HRD-negative, BRCA wild type with ATM variant; PARP benefit uncertain, prioritize conventional systemic options or trials. [@OH2203828|2022-04-18]\n\n- Critical missing data: histology/grade, initial stage, prior treatments and responses, current ECOG, symptoms, and patient preferences/goals.", "timestamp": "2026-01-18T17:38:01.425618"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before committing to further systemic therapy, please urgently clarify anemia etiology and ECOG/symptoms, and retrieve full pathology/treatment history to confirm disease classification and realistic treatment intensity.\",\"why\":\"safety\"},{\"target\":\"nuclear\",\"message\":\"PET/CT should only be pursued if it will concretely influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting.\",\"why\":\"safety\"}]}", "timestamp": "2026-01-18T17:38:24.460114"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n[R1T1 DELTA] influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting. | oncologist->chair(safety): Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented. | oncologist->nuclear(missing): PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility. | pathologist->oncologist(missing): Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification. | pathologist->chair(missing): Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Please formalize that systemic treatment intensity is deferred until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\",\"why\":\"safety\"},{\"target\":\"pathologist\",\"message\":\"Kindly prioritize retrieval/review of all original and recurrence pathology with full histology, grade, and IHC so that ongoing management is not based on an unconfirmed primary/site.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T17:38:33.312167"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n[R1T1 DELTA] influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting. | oncologist->chair(safety): Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented. | oncologist->nuclear(missing): PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility. | pathologist->oncologist(missing): Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification. | pathologist->chair(missing): Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.\n[R1T2 DELTA] oncologist(safety): Please formalize that systemic treatment intensity is deferred until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented. | chair->pathologist(missing): Kindly prioritize retrieval/review of all original and recurrence pathology with full histology, grade, and IHC so that ongoing management is not based on an unconfirmed primary/site. | nuclear->oncologist(missing): From a nuclear perspective, PET/CT is optional but could meaningfully refine bone and whole‑body disease mapping if you’re considering targeted palliative radiotherapy or trial screening that requires precise metastatic documentation. | nuclear->radiologist(missing): If PET/CT is obtained, please correlate FDG‑avid bone and liver lesions with prior CT/MR to distinguish metastases from benign/incidental findings for radiotherapy planning.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Confirm non-curative, symptom-focused intent and involve palliative care for pain, pelvic, bowel, and liver-related symptom control.  \n\n- Defer systemic treatment intensity decisions until anemia work-up, ECOG, symptom burden, and patient goals are documented; provide transfusion/supportive care meanwhile. [@20230103|5600862]  \n\n- Urgently retrieve and review all original and recurrence pathology (histology, grade, IHC, primary site) plus full treatment history; current status unknown.  \n\n- Consider PET/CT only if results will change palliative radiotherapy targeting (e.g., sacrum/iliac bone/liver) or clinical trial eligibility; otherwise optional. [@2022-12-29|MR; @2022-12-29|CT]  \n\n- Plan next MDT after pathology/treatment history, anemia evaluation, ECOG, and updated labs/biomarkers are available to individualize systemic/palliative strategies.", "timestamp": "2026-01-18T17:38:42.892010"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver metastases, and new suspected iliac bone metastasis → non‑curative intent.\n- Severe anemia (Hgb 74 g/L) is a major constraint on systemic therapy; liver/renal function currently compatible with treatment if ECOG is acceptable.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic‑type malignancy.\n- HRD negative, BRCA1/2 wild type with ATM variant of uncertain significance → limited expected benefit from PARP; conventional systemic options or trials more relevant.\n\nControversies:\n- Unconfirmed primary site and histologic subtype (ovarian vs other gynecologic/pelvic origin); original stage unclear.\n- Systemic treatment intensity and feasibility cannot be decided safely without anemia work‑up, ECOG, and documented patient goals.\n- PET/CT considered optional in a clearly metastatic, non‑curative setting; potential role only if it would influence palliative radiotherapy planning, systemic strategy, or trial eligibility.\n\nMissing Info:\n- Pathology: original and recurrence reports with histology, grade, IHC, primary site confirmation, and staging; current decisions are being made without a fully confirmed histologic diagnosis.\n- Treatment history: prior systemic and radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences and goals of care.\n- Hematology: anemia etiology, iron/B12/folate status, hemolysis/bleeding assessment, transfusion history.\n- Updated labs/biomarkers: full biochemistry including eGFR, electrolytes, LFTs; somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline to map metabolic extent of visceral and bone disease.\n\nWorking Plan:\n- Reaffirm non‑curative, symptom‑focused intent and engage palliative care for pain and pelvic/visceral symptom control.\n- Urgently complete anemia work‑up and provide transfusion/supportive measures before any decision on systemic treatment intensity.\n- Formalize that systemic therapy intensity is deferred until anemia evaluation, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, and IHC to confirm primary/site.\n- Consider PET/CT only if results are needed to guide palliative radiotherapy targeting or to meet documentation requirements for clinical trials, with radiology–nuclear correlation for bone/liver lesions.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T17:39:35.153090"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver metastases, and new suspected iliac bone metastasis → non‑curative intent.\n- Severe anemia (Hgb 74 g/L) is a major constraint on systemic therapy; liver/renal function currently compatible with treatment if ECOG is acceptable.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic‑type malignancy.\n- HRD negative, BRCA1/2 wild type with ATM variant of uncertain significance → limited expected benefit from PARP; conventional systemic options or trials more relevant.\n\nControversies:\n- Unconfirmed primary site and histologic subtype (ovarian vs other gynecologic/pelvic origin); original stage unclear.\n- Systemic treatment intensity and feasibility cannot be decided safely without anemia work‑up, ECOG, and documented patient goals.\n- PET/CT considered optional in a clearly metastatic, non‑curative setting; potential role only if it would influence palliative radiotherapy planning, systemic strategy, or trial eligibility.\n\nMissing Info:\n- Pathology: original and recurrence reports with histology, grade, IHC, primary site confirmation, and staging; current decisions are being made without a fully confirmed histologic diagnosis.\n- Treatment history: prior systemic and radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences and goals of care.\n- Hematology: anemia etiology, iron/B12/folate status, hemolysis/bleeding assessment, transfusion history.\n- Updated labs/biomarkers: full biochemistry including eGFR, electrolytes, LFTs; somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline to map metabolic extent of visceral and bone disease.\n\nWorking Plan:\n- Reaffirm non‑curative, symptom‑focused intent and engage palliative care for pain and pelvic/visceral symptom control.\n- Urgently complete anemia work‑up and provide transfusion/supportive measures before any decision on systemic treatment intensity.\n- Formalize that systemic therapy intensity is deferred until anemia evaluation, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, and IHC to confirm primary/site.\n- Consider PET/CT only if results are needed to guide palliative radiotherapy targeting or to meet documentation requirements for clinical trials, with radiology–nuclear correlation for bone/liver lesions.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Reaffirm non-curative, symptom-focused intent and engage palliative care for pain and pelvic/visceral symptom control; primary site still unknown.  \n\n- Urgently investigate anemia etiology and give transfusion/supportive care before deciding on systemic treatment intensity. [@20230103|5600862]  \n\n- Defer systemic therapy intensity until anemia work-up, ECOG, symptom burden, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \n\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, IHC, and staging; currently unknown.  \n\n- Reserve PET/CT for situations where findings would alter palliative radiotherapy fields (sacrum/iliac/liver) or clinical trial eligibility; otherwise optional.", "timestamp": "2026-01-18T17:40:02.035187"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-03 08:53:29.260000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@report_id|date] or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id|page] or [@pubmed:PMID].\n- If experts disagree, pick the safest plan and state the key uncertainty.\n\n# FINAL REFINED PLANS (All experts, last round)\n{\n  \"Round 1\": {\n    \"chair\": \"- Confirm non-curative, symptom-focused intent and involve palliative care for pain, pelvic, bowel, and liver-related symptom control.  \\n\\n- Defer systemic treatment intensity decisions until anemia work-up, ECOG, symptom burden, and patient goals are documented; provide transfusion/supportive care meanwhile. [@20230103|5600862]  \\n\\n- Urgently retrieve and review all original and recurrence pathology (histology, grade, IHC, primary site) plus full treatment history; current status unknown.  \\n\\n- Consider PET/CT only if results will change palliative radiotherapy targeting (e.g., sacrum/iliac bone/liver) or clinical trial eligibility; otherwise optional. [@2022-12-29|MR; @2022-12-29|CT]  \\n\\n- Plan next MDT after pathology/treatment history, anemia evaluation, ECOG, and updated labs/biomarkers are available to individualize systemic/palliative strategies.\",\n    \"oncologist\": \"- Defer systemic treatment intensity decisions until anemia work-up, ECOG performance, symptoms, and patient goals are fully documented. [@20230103|2023-01-03]  \\n\\n- Urgently investigate and treat anemia (iron/B12/folate, bleeding/hemolysis, transfusion support) before any new systemic regimen. [@20230103|2023-01-03]  \\n\\n- Retrieve and review complete pathology (initial and recurrence histology, grade, IHC) to clarify primary site and subtype; current status unknown.  \\n\\n- Maintain non-curative, symptom-focused intent with early palliative care involvement for pelvic pain, bowel/bladder issues, and liver/bone symptoms.  \\n\\n- Consider PET/CT only if results will change palliative radiotherapy planning, systemic strategy, or clinical trial eligibility; currently optional.\",\n    \"radiologist\": \"- Progressive presacral mass invading sacrum/peritoneum with probable vaginal stump/rectal involvement; symptomatic course likely, curative local control unrealistic.[@2022-12-29|MR]\\n\\n- Liver metastases increased in number and size, confirming disseminated visceral disease burden in a non‑curative context.[@2022-12-29|CT]\\n\\n- New right iliac bone enhancing nodule suspicious for bone metastasis; may become relevant for targeted palliative radiotherapy.[@2022-12-29|MR]\\n\\n- Pelvic/mesenteric peritoneal nodules stable, representing persistent peritoneal dissemination without clear radiologic obstruction currently.[@2022-12-29|MR]\\n\\n- PET/CT remains optional; consider only if it would alter palliative radiotherapy fields or trial eligibility via better metastatic mapping.[@2022-12-29|CT]\",\n    \"pathologist\": \"- Systemic treatment intensity is deferred until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \\n- Pathology team to urgently retrieve and review all original and recurrence specimens with full histology, grade, and IHC; primary site currently unknown.  \\n- Maintain non‑curative, symptom‑focused intent; involve palliative care for pain and pelvic/visceral symptom management (clinical status details currently unknown).  \\n- PET/CT is optional; consider only if it will guide targeted palliative radiotherapy planning or trial eligibility requiring precise metastatic mapping.  \\n- Once anemia etiology, performance status, patient preferences, and definitive pathology are available, the oncology team will reassess systemic strategy and trial options.\",\n    \"nuclear\": \"- Maintain non‑curative, symptom‑focused intent; involve palliative care for pelvic pain and visceral symptom management (clinical status details unknown).  \\n\\n- Defer systemic treatment intensity decisions until anemia work‑up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \\n\\n- Pathology team to urgently retrieve/review all original and recurrence specimens with full histology, grade, and IHC; current primary/site remains unconfirmed.  \\n\\n- PET/CT is optional; obtain only if results would change palliative radiotherapy fields, systemic strategy, or clinical trial eligibility (no prior PET/CT).  \\n\\n- If PET/CT performed, integrate FDG findings with CT/MR to confirm bone (right iliac) and liver metastases for radiotherapy planning. [@2022-12-29|MR; @2022-12-29|CT]\"\n  },\n  \"Round 2\": {\n    \"chair\": \"- Reaffirm non-curative, symptom-focused intent and engage palliative care for pain and pelvic/visceral symptom control; primary site still unknown.  \\n\\n- Urgently investigate anemia etiology and give transfusion/supportive care before deciding on systemic treatment intensity. [@20230103|5600862]  \\n\\n- Defer systemic therapy intensity until anemia work-up, ECOG, symptom burden, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \\n\\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, IHC, and staging; currently unknown.  \\n\\n- Reserve PET/CT for situations where findings would alter palliative radiotherapy fields (sacrum/iliac/liver) or clinical trial eligibility; otherwise optional.\",\n    \"oncologist\": \"- Reaffirm non-curative, symptom-focused intent and involve palliative care early for pelvic, visceral, and potential bone symptom management; staging details unknown.  \\n\\n- Urgently investigate and treat severe anemia before systemic therapy decisions (iron/B12/folate, bleeding/hemolysis, transfusion as needed). [@20230103|2023-01-03]  \\n\\n- Defer systemic treatment intensity until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented; currently unknown.  \\n\\n- Pathology to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, IHC, and staging; currently unknown.  \\n\\n- Consider PET/CT only if findings would change palliative radiotherapy targeting, systemic strategy, or satisfy clinical trial documentation requirements; currently optional.\",\n    \"radiologist\": \"- Presacral pelvic mass with sacral/peritoneal invasion and probable vaginal stump/rectal involvement indicates progressive, locally advanced recurrent disease.[@2022-12-29|MR]\\n\\n- Liver metastases have increased in number and size, confirming progression of disseminated visceral disease.[@2022-12-29|CT]\\n\\n- New right iliac bone enhancing nodule remains suspicious for bone metastasis and may guide future palliative radiotherapy targeting.[@2022-12-29|MR]\\n\\n- Pelvic/mesenteric peritoneal nodules are stable, representing persistent peritoneal dissemination without current radiologic obstruction.[@2022-12-29|MR]\\n\\n- PET/CT stays optional; obtain only if needed to refine radiotherapy fields or trial-required metastatic mapping.[@2022-12-29|CT]\",\n    \"pathologist\": \"- Maintain non‑curative, symptom‑focused intent; engage palliative care for pain and pelvic/visceral symptom control (clinical details currently unknown).  \\n- Defer systemic therapy intensity until anemia work‑up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \\n- Pathology team to urgently retrieve/review all original and recurrence specimens with full histology, grade, IHC, and staging; primary/site currently unknown.  \\n- Complete anemia evaluation (iron/B12/folate, hemolysis/bleeding, transfusion history) and provide supportive care before revisiting systemic options (lab details unknown).  \\n- Use PET/CT only if needed for precise palliative radiotherapy targeting or to fulfill clinical trial metastatic documentation requirements.\",\n    \"nuclear\": \"- Non‑curative, symptom‑focused intent remains appropriate; engage palliative care for pelvic and visceral symptom management (clinical details currently unknown).  \\n\\n- Defer systemic treatment intensity until anemia work‑up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \\n\\n- Pathology team to urgently retrieve/review all original and recurrence specimens with full histology, grade, IHC, and staging (currently unknown).  \\n\\n- PET/CT is optional; perform only if it will guide palliative radiotherapy targeting or clinical‑trial eligibility (no prior PET/CT available).  \\n\\n- If PET/CT obtained, correlate FDG‑avid bone and liver lesions with CT/MR to confirm metastases for radiotherapy planning. [@2022-12-29|MR; @2022-12-29|CT]\"\n  }\n}\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words “if X, then adjust management from A to B” >\n- < ≤20 words “if X, then adjust management from A to B” >\n", "assistant_reply": "Final Assessment:\nDisseminated recurrent gynecologic malignancy with progressive pelvic, liver, and probable bone involvement in a non‑curative setting; histologic subtype, primary site, performance status, and anemia etiology remain unresolved. [@2022-12-29|MR; @2022-12-29|CT; @20230103|5600862]\n\nCore Treatment Strategy:\n- Maintain non‑curative, symptom‑focused intent and engage palliative care for pain, bowel/bladder, and liver/bone symptom management.  \n- Urgently evaluate severe anemia (iron/B12/folate, bleeding/hemolysis) and provide transfusion/supportive care before systemic therapy decisions. [@20230103|5600862]  \n- Expedite retrieval/review of all pathology (initial and recurrence histology, IHC, staging) and full prior treatment history; currently unknown.  \n- Defer new systemic treatment intensity and any radiotherapy planning until anemia work‑up, ECOG status, pathology clarification, and patient goals are documented.  \n\nChange Triggers:\n- If anemia stabilized and ECOG acceptable, then revisit suitability and goals of systemic therapy versus best supportive care focus.  \n- If pathology/treatment history clarify primary site and subtype, then individualize systemic and radiotherapy strategies per disease biology and prior exposure.", "timestamp": "2026-01-18T17:40:40.601057"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Tumor markers CA125, CA19-9, CA15-3 markedly elevated, supporting active gynecologic malignancy; histologic diagnosis and stage unknown/needs update. [@20221229|9703212]\n\n- Severe anemia (Hgb 74 g/L) likely limits intensity of cytotoxic therapy; etiology and transfusion/iron status unknown/needs update. [@20230103|5600862]\n\n- Renal and hepatic function acceptable for most systemic agents, but full panel including electrolytes and eGFR confirmation needed. [@20221229|8300002]\n\n- HRD negative, BRCA1/2 negative, germline ATM variant identified; implications for targeted therapy modest. [@OH2203828|2022-04-18]\n\n- Missing: exact cancer diagnosis, prior systemic treatments, treatment response, performance status, current disease burden/imaging to define line and intent.", "timestamp": "2026-01-18T17:38:04.272573"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented.\",\"why\":\"safety\"},{\"target\":\"nuclear\",\"message\":\"PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T17:38:26.387874"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n[R1T1 DELTA] influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting. | oncologist->chair(safety): Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented. | oncologist->nuclear(missing): PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility. | pathologist->oncologist(missing): Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification. | pathologist->chair(missing): Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T17:38:34.684921"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n[R1T1 DELTA] influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting. | oncologist->chair(safety): Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented. | oncologist->nuclear(missing): PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility. | pathologist->oncologist(missing): Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification. | pathologist->chair(missing): Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.\n[R1T2 DELTA] oncologist(safety): Please formalize that systemic treatment intensity is deferred until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented. | chair->pathologist(missing): Kindly prioritize retrieval/review of all original and recurrence pathology with full histology, grade, and IHC so that ongoing management is not based on an unconfirmed primary/site. | nuclear->oncologist(missing): From a nuclear perspective, PET/CT is optional but could meaningfully refine bone and whole‑body disease mapping if you’re considering targeted palliative radiotherapy or trial screening that requires precise metastatic documentation. | nuclear->radiologist(missing): If PET/CT is obtained, please correlate FDG‑avid bone and liver lesions with prior CT/MR to distinguish metastases from benign/incidental findings for radiotherapy planning.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Defer systemic treatment intensity decisions until anemia work-up, ECOG performance, symptoms, and patient goals are fully documented. [@20230103|2023-01-03]  \n\n- Urgently investigate and treat anemia (iron/B12/folate, bleeding/hemolysis, transfusion support) before any new systemic regimen. [@20230103|2023-01-03]  \n\n- Retrieve and review complete pathology (initial and recurrence histology, grade, IHC) to clarify primary site and subtype; current status unknown.  \n\n- Maintain non-curative, symptom-focused intent with early palliative care involvement for pelvic pain, bowel/bladder issues, and liver/bone symptoms.  \n\n- Consider PET/CT only if results will change palliative radiotherapy planning, systemic strategy, or clinical trial eligibility; currently optional.", "timestamp": "2026-01-18T17:38:58.328311"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver metastases, and new suspected iliac bone metastasis → non‑curative intent.\n- Severe anemia (Hgb 74 g/L) is a major constraint on systemic therapy; liver/renal function currently compatible with treatment if ECOG is acceptable.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic‑type malignancy.\n- HRD negative, BRCA1/2 wild type with ATM variant of uncertain significance → limited expected benefit from PARP; conventional systemic options or trials more relevant.\n\nControversies:\n- Unconfirmed primary site and histologic subtype (ovarian vs other gynecologic/pelvic origin); original stage unclear.\n- Systemic treatment intensity and feasibility cannot be decided safely without anemia work‑up, ECOG, and documented patient goals.\n- PET/CT considered optional in a clearly metastatic, non‑curative setting; potential role only if it would influence palliative radiotherapy planning, systemic strategy, or trial eligibility.\n\nMissing Info:\n- Pathology: original and recurrence reports with histology, grade, IHC, primary site confirmation, and staging; current decisions are being made without a fully confirmed histologic diagnosis.\n- Treatment history: prior systemic and radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences and goals of care.\n- Hematology: anemia etiology, iron/B12/folate status, hemolysis/bleeding assessment, transfusion history.\n- Updated labs/biomarkers: full biochemistry including eGFR, electrolytes, LFTs; somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline to map metabolic extent of visceral and bone disease.\n\nWorking Plan:\n- Reaffirm non‑curative, symptom‑focused intent and engage palliative care for pain and pelvic/visceral symptom control.\n- Urgently complete anemia work‑up and provide transfusion/supportive measures before any decision on systemic treatment intensity.\n- Formalize that systemic therapy intensity is deferred until anemia evaluation, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, and IHC to confirm primary/site.\n- Consider PET/CT only if results are needed to guide palliative radiotherapy targeting or to meet documentation requirements for clinical trials, with radiology–nuclear correlation for bone/liver lesions.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T17:39:36.687034"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver metastases, and new suspected iliac bone metastasis → non‑curative intent.\n- Severe anemia (Hgb 74 g/L) is a major constraint on systemic therapy; liver/renal function currently compatible with treatment if ECOG is acceptable.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic‑type malignancy.\n- HRD negative, BRCA1/2 wild type with ATM variant of uncertain significance → limited expected benefit from PARP; conventional systemic options or trials more relevant.\n\nControversies:\n- Unconfirmed primary site and histologic subtype (ovarian vs other gynecologic/pelvic origin); original stage unclear.\n- Systemic treatment intensity and feasibility cannot be decided safely without anemia work‑up, ECOG, and documented patient goals.\n- PET/CT considered optional in a clearly metastatic, non‑curative setting; potential role only if it would influence palliative radiotherapy planning, systemic strategy, or trial eligibility.\n\nMissing Info:\n- Pathology: original and recurrence reports with histology, grade, IHC, primary site confirmation, and staging; current decisions are being made without a fully confirmed histologic diagnosis.\n- Treatment history: prior systemic and radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences and goals of care.\n- Hematology: anemia etiology, iron/B12/folate status, hemolysis/bleeding assessment, transfusion history.\n- Updated labs/biomarkers: full biochemistry including eGFR, electrolytes, LFTs; somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline to map metabolic extent of visceral and bone disease.\n\nWorking Plan:\n- Reaffirm non‑curative, symptom‑focused intent and engage palliative care for pain and pelvic/visceral symptom control.\n- Urgently complete anemia work‑up and provide transfusion/supportive measures before any decision on systemic treatment intensity.\n- Formalize that systemic therapy intensity is deferred until anemia evaluation, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, and IHC to confirm primary/site.\n- Consider PET/CT only if results are needed to guide palliative radiotherapy targeting or to meet documentation requirements for clinical trials, with radiology–nuclear correlation for bone/liver lesions.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Reaffirm non-curative, symptom-focused intent and involve palliative care early for pelvic, visceral, and potential bone symptom management; staging details unknown.  \n\n- Urgently investigate and treat severe anemia before systemic therapy decisions (iron/B12/folate, bleeding/hemolysis, transfusion as needed). [@20230103|2023-01-03]  \n\n- Defer systemic treatment intensity until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented; currently unknown.  \n\n- Pathology to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, IHC, and staging; currently unknown.  \n\n- Consider PET/CT only if findings would change palliative radiotherapy targeting, systemic strategy, or satisfy clinical trial documentation requirements; currently optional.", "timestamp": "2026-01-18T17:40:06.335494"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Presacral pelvic mass enlarged to ~53×44 mm with more heterogeneous signal; involves adjacent peritoneum and sacrum, suggesting progressive local recurrence.[@2022-12-29|MR]\n\n- Persistent thickened vaginal stump and enhancing rectal wall segment adjacent to mass, raising concern for direct local involvement.[@2022-12-29|MR]\n\n- New enhancing nodule in right iliac bone, suspicious for osseous metastasis.[@2022-12-29|MR]\n\n- Multiple enhancing mesenteric/pelvic nodules unchanged, compatible with stable peritoneal metastatic disease.[@2022-12-29|MR]\n\n- Liver: multiple metastatic lesions increased in number and size; additional stable hepatic cysts and possible splenic infarct needing follow‑up.[@2022-12-29|CT]", "timestamp": "2026-01-18T17:38:06.781234"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T17:38:27.780031"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n[R1T1 DELTA] influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting. | oncologist->chair(safety): Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented. | oncologist->nuclear(missing): PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility. | pathologist->oncologist(missing): Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification. | pathologist->chair(missing): Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T17:38:36.019886"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n[R1T1 DELTA] influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting. | oncologist->chair(safety): Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented. | oncologist->nuclear(missing): PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility. | pathologist->oncologist(missing): Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification. | pathologist->chair(missing): Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.\n[R1T2 DELTA] oncologist(safety): Please formalize that systemic treatment intensity is deferred until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented. | chair->pathologist(missing): Kindly prioritize retrieval/review of all original and recurrence pathology with full histology, grade, and IHC so that ongoing management is not based on an unconfirmed primary/site. | nuclear->oncologist(missing): From a nuclear perspective, PET/CT is optional but could meaningfully refine bone and whole‑body disease mapping if you’re considering targeted palliative radiotherapy or trial screening that requires precise metastatic documentation. | nuclear->radiologist(missing): If PET/CT is obtained, please correlate FDG‑avid bone and liver lesions with prior CT/MR to distinguish metastases from benign/incidental findings for radiotherapy planning.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Progressive presacral mass invading sacrum/peritoneum with probable vaginal stump/rectal involvement; symptomatic course likely, curative local control unrealistic.[@2022-12-29|MR]\n\n- Liver metastases increased in number and size, confirming disseminated visceral disease burden in a non‑curative context.[@2022-12-29|CT]\n\n- New right iliac bone enhancing nodule suspicious for bone metastasis; may become relevant for targeted palliative radiotherapy.[@2022-12-29|MR]\n\n- Pelvic/mesenteric peritoneal nodules stable, representing persistent peritoneal dissemination without clear radiologic obstruction currently.[@2022-12-29|MR]\n\n- PET/CT remains optional; consider only if it would alter palliative radiotherapy fields or trial eligibility via better metastatic mapping.[@2022-12-29|CT]", "timestamp": "2026-01-18T17:39:05.614855"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver metastases, and new suspected iliac bone metastasis → non‑curative intent.\n- Severe anemia (Hgb 74 g/L) is a major constraint on systemic therapy; liver/renal function currently compatible with treatment if ECOG is acceptable.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic‑type malignancy.\n- HRD negative, BRCA1/2 wild type with ATM variant of uncertain significance → limited expected benefit from PARP; conventional systemic options or trials more relevant.\n\nControversies:\n- Unconfirmed primary site and histologic subtype (ovarian vs other gynecologic/pelvic origin); original stage unclear.\n- Systemic treatment intensity and feasibility cannot be decided safely without anemia work‑up, ECOG, and documented patient goals.\n- PET/CT considered optional in a clearly metastatic, non‑curative setting; potential role only if it would influence palliative radiotherapy planning, systemic strategy, or trial eligibility.\n\nMissing Info:\n- Pathology: original and recurrence reports with histology, grade, IHC, primary site confirmation, and staging; current decisions are being made without a fully confirmed histologic diagnosis.\n- Treatment history: prior systemic and radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences and goals of care.\n- Hematology: anemia etiology, iron/B12/folate status, hemolysis/bleeding assessment, transfusion history.\n- Updated labs/biomarkers: full biochemistry including eGFR, electrolytes, LFTs; somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline to map metabolic extent of visceral and bone disease.\n\nWorking Plan:\n- Reaffirm non‑curative, symptom‑focused intent and engage palliative care for pain and pelvic/visceral symptom control.\n- Urgently complete anemia work‑up and provide transfusion/supportive measures before any decision on systemic treatment intensity.\n- Formalize that systemic therapy intensity is deferred until anemia evaluation, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, and IHC to confirm primary/site.\n- Consider PET/CT only if results are needed to guide palliative radiotherapy targeting or to meet documentation requirements for clinical trials, with radiology–nuclear correlation for bone/liver lesions.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T17:39:38.267221"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver metastases, and new suspected iliac bone metastasis → non‑curative intent.\n- Severe anemia (Hgb 74 g/L) is a major constraint on systemic therapy; liver/renal function currently compatible with treatment if ECOG is acceptable.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic‑type malignancy.\n- HRD negative, BRCA1/2 wild type with ATM variant of uncertain significance → limited expected benefit from PARP; conventional systemic options or trials more relevant.\n\nControversies:\n- Unconfirmed primary site and histologic subtype (ovarian vs other gynecologic/pelvic origin); original stage unclear.\n- Systemic treatment intensity and feasibility cannot be decided safely without anemia work‑up, ECOG, and documented patient goals.\n- PET/CT considered optional in a clearly metastatic, non‑curative setting; potential role only if it would influence palliative radiotherapy planning, systemic strategy, or trial eligibility.\n\nMissing Info:\n- Pathology: original and recurrence reports with histology, grade, IHC, primary site confirmation, and staging; current decisions are being made without a fully confirmed histologic diagnosis.\n- Treatment history: prior systemic and radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences and goals of care.\n- Hematology: anemia etiology, iron/B12/folate status, hemolysis/bleeding assessment, transfusion history.\n- Updated labs/biomarkers: full biochemistry including eGFR, electrolytes, LFTs; somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline to map metabolic extent of visceral and bone disease.\n\nWorking Plan:\n- Reaffirm non‑curative, symptom‑focused intent and engage palliative care for pain and pelvic/visceral symptom control.\n- Urgently complete anemia work‑up and provide transfusion/supportive measures before any decision on systemic treatment intensity.\n- Formalize that systemic therapy intensity is deferred until anemia evaluation, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, and IHC to confirm primary/site.\n- Consider PET/CT only if results are needed to guide palliative radiotherapy targeting or to meet documentation requirements for clinical trials, with radiology–nuclear correlation for bone/liver lesions.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Presacral pelvic mass with sacral/peritoneal invasion and probable vaginal stump/rectal involvement indicates progressive, locally advanced recurrent disease.[@2022-12-29|MR]\n\n- Liver metastases have increased in number and size, confirming progression of disseminated visceral disease.[@2022-12-29|CT]\n\n- New right iliac bone enhancing nodule remains suspicious for bone metastasis and may guide future palliative radiotherapy targeting.[@2022-12-29|MR]\n\n- Pelvic/mesenteric peritoneal nodules are stable, representing persistent peritoneal dissemination without current radiologic obstruction.[@2022-12-29|MR]\n\n- PET/CT stays optional; obtain only if needed to refine radiotherapy fields or trial-required metastatic mapping.[@2022-12-29|CT]", "timestamp": "2026-01-18T17:40:31.832706"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- No histology, grade, site, or IHC results are available; primary diagnosis cannot be confirmed or classified.  \n- Germline ATM exon8 c.A947G:p.Y316C variant reported; clinical significance (pathogenic vs VUS) not specified. [@OH2203828|2022-04-18]  \n- HRD testing reported negative; BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 pathogenic variants not detected. [@OH2203828|2022-04-18]  \n- Tumor somatic NGS panel, MSI/MMR, TMB, and PD-L1 status unknown/needs update.  \n- Full surgical pathology report (histotype, grade, stage, margins, residual disease) and IHC panel results unknown/needs update.", "timestamp": "2026-01-18T17:38:09.336141"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification.\",\"why\":\"missing\"},{\"target\":\"chair\",\"message\":\"Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T17:38:29.825781"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n[R1T1 DELTA] influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting. | oncologist->chair(safety): Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented. | oncologist->nuclear(missing): PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility. | pathologist->oncologist(missing): Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification. | pathologist->chair(missing): Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T17:38:37.612771"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n[R1T1 DELTA] influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting. | oncologist->chair(safety): Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented. | oncologist->nuclear(missing): PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility. | pathologist->oncologist(missing): Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification. | pathologist->chair(missing): Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.\n[R1T2 DELTA] oncologist(safety): Please formalize that systemic treatment intensity is deferred until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented. | chair->pathologist(missing): Kindly prioritize retrieval/review of all original and recurrence pathology with full histology, grade, and IHC so that ongoing management is not based on an unconfirmed primary/site. | nuclear->oncologist(missing): From a nuclear perspective, PET/CT is optional but could meaningfully refine bone and whole‑body disease mapping if you’re considering targeted palliative radiotherapy or trial screening that requires precise metastatic documentation. | nuclear->radiologist(missing): If PET/CT is obtained, please correlate FDG‑avid bone and liver lesions with prior CT/MR to distinguish metastases from benign/incidental findings for radiotherapy planning.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Systemic treatment intensity is deferred until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \n- Pathology team to urgently retrieve and review all original and recurrence specimens with full histology, grade, and IHC; primary site currently unknown.  \n- Maintain non‑curative, symptom‑focused intent; involve palliative care for pain and pelvic/visceral symptom management (clinical status details currently unknown).  \n- PET/CT is optional; consider only if it will guide targeted palliative radiotherapy planning or trial eligibility requiring precise metastatic mapping.  \n- Once anemia etiology, performance status, patient preferences, and definitive pathology are available, the oncology team will reassess systemic strategy and trial options.", "timestamp": "2026-01-18T17:39:17.861840"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver metastases, and new suspected iliac bone metastasis → non‑curative intent.\n- Severe anemia (Hgb 74 g/L) is a major constraint on systemic therapy; liver/renal function currently compatible with treatment if ECOG is acceptable.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic‑type malignancy.\n- HRD negative, BRCA1/2 wild type with ATM variant of uncertain significance → limited expected benefit from PARP; conventional systemic options or trials more relevant.\n\nControversies:\n- Unconfirmed primary site and histologic subtype (ovarian vs other gynecologic/pelvic origin); original stage unclear.\n- Systemic treatment intensity and feasibility cannot be decided safely without anemia work‑up, ECOG, and documented patient goals.\n- PET/CT considered optional in a clearly metastatic, non‑curative setting; potential role only if it would influence palliative radiotherapy planning, systemic strategy, or trial eligibility.\n\nMissing Info:\n- Pathology: original and recurrence reports with histology, grade, IHC, primary site confirmation, and staging; current decisions are being made without a fully confirmed histologic diagnosis.\n- Treatment history: prior systemic and radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences and goals of care.\n- Hematology: anemia etiology, iron/B12/folate status, hemolysis/bleeding assessment, transfusion history.\n- Updated labs/biomarkers: full biochemistry including eGFR, electrolytes, LFTs; somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline to map metabolic extent of visceral and bone disease.\n\nWorking Plan:\n- Reaffirm non‑curative, symptom‑focused intent and engage palliative care for pain and pelvic/visceral symptom control.\n- Urgently complete anemia work‑up and provide transfusion/supportive measures before any decision on systemic treatment intensity.\n- Formalize that systemic therapy intensity is deferred until anemia evaluation, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, and IHC to confirm primary/site.\n- Consider PET/CT only if results are needed to guide palliative radiotherapy targeting or to meet documentation requirements for clinical trials, with radiology–nuclear correlation for bone/liver lesions.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T17:39:39.743226"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver metastases, and new suspected iliac bone metastasis → non‑curative intent.\n- Severe anemia (Hgb 74 g/L) is a major constraint on systemic therapy; liver/renal function currently compatible with treatment if ECOG is acceptable.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic‑type malignancy.\n- HRD negative, BRCA1/2 wild type with ATM variant of uncertain significance → limited expected benefit from PARP; conventional systemic options or trials more relevant.\n\nControversies:\n- Unconfirmed primary site and histologic subtype (ovarian vs other gynecologic/pelvic origin); original stage unclear.\n- Systemic treatment intensity and feasibility cannot be decided safely without anemia work‑up, ECOG, and documented patient goals.\n- PET/CT considered optional in a clearly metastatic, non‑curative setting; potential role only if it would influence palliative radiotherapy planning, systemic strategy, or trial eligibility.\n\nMissing Info:\n- Pathology: original and recurrence reports with histology, grade, IHC, primary site confirmation, and staging; current decisions are being made without a fully confirmed histologic diagnosis.\n- Treatment history: prior systemic and radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences and goals of care.\n- Hematology: anemia etiology, iron/B12/folate status, hemolysis/bleeding assessment, transfusion history.\n- Updated labs/biomarkers: full biochemistry including eGFR, electrolytes, LFTs; somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline to map metabolic extent of visceral and bone disease.\n\nWorking Plan:\n- Reaffirm non‑curative, symptom‑focused intent and engage palliative care for pain and pelvic/visceral symptom control.\n- Urgently complete anemia work‑up and provide transfusion/supportive measures before any decision on systemic treatment intensity.\n- Formalize that systemic therapy intensity is deferred until anemia evaluation, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, and IHC to confirm primary/site.\n- Consider PET/CT only if results are needed to guide palliative radiotherapy targeting or to meet documentation requirements for clinical trials, with radiology–nuclear correlation for bone/liver lesions.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Maintain non‑curative, symptom‑focused intent; engage palliative care for pain and pelvic/visceral symptom control (clinical details currently unknown).  \n- Defer systemic therapy intensity until anemia work‑up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \n- Pathology team to urgently retrieve/review all original and recurrence specimens with full histology, grade, IHC, and staging; primary/site currently unknown.  \n- Complete anemia evaluation (iron/B12/folate, hemolysis/bleeding, transfusion history) and provide supportive care before revisiting systemic options (lab details unknown).  \n- Use PET/CT only if needed for precise palliative radiotherapy targeting or to fulfill clinical trial metastatic documentation requirements.", "timestamp": "2026-01-18T17:40:34.403696"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- No prior PET/CT available; baseline metabolic characterization of pelvic, hepatic, and osseous lesions is unknown/needs PET-CT update.\n\n- MRI shows enlarging presacral mass with sacrum and peritoneal involvement, highly suspicious for local pelvic recurrence. [@2022-12-29|MR]\n\n- New right iliac bone enhancing lesion on MRI suggests possible osseous metastasis; PET could confirm metabolic activity and extent. [@2022-12-29|MR]\n\n- CT shows multiple increasing liver lesions consistent with metastases; PET may refine lesion count and confirm active disease burden. [@2022-12-29|CT]\n\n- PET/CT now would help refine staging (visceral and bone metastases vs localized recurrence) and guide future management planning.", "timestamp": "2026-01-18T17:38:11.892649"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T17:38:31.153492"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n[R1T1 DELTA] influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting. | oncologist->chair(safety): Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented. | oncologist->nuclear(missing): PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility. | pathologist->oncologist(missing): Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification. | pathologist->chair(missing): Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"From a nuclear perspective, PET/CT is optional but could meaningfully refine bone and whole‑body disease mapping if you’re considering targeted palliative radiotherapy or trial screening that requires precise metastatic documentation.\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"If PET/CT is obtained, please correlate FDG‑avid bone and liver lesions with prior CT/MR to distinguish metastases from benign/incidental findings for radiotherapy planning.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T17:38:39.890907"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n[R1T1 DELTA] influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting. | oncologist->chair(safety): Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented. | oncologist->nuclear(missing): PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility. | pathologist->oncologist(missing): Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification. | pathologist->chair(missing): Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.\n[R1T2 DELTA] oncologist(safety): Please formalize that systemic treatment intensity is deferred until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented. | chair->pathologist(missing): Kindly prioritize retrieval/review of all original and recurrence pathology with full histology, grade, and IHC so that ongoing management is not based on an unconfirmed primary/site. | nuclear->oncologist(missing): From a nuclear perspective, PET/CT is optional but could meaningfully refine bone and whole‑body disease mapping if you’re considering targeted palliative radiotherapy or trial screening that requires precise metastatic documentation. | nuclear->radiologist(missing): If PET/CT is obtained, please correlate FDG‑avid bone and liver lesions with prior CT/MR to distinguish metastases from benign/incidental findings for radiotherapy planning.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Maintain non‑curative, symptom‑focused intent; involve palliative care for pelvic pain and visceral symptom management (clinical status details unknown).  \n\n- Defer systemic treatment intensity decisions until anemia work‑up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \n\n- Pathology team to urgently retrieve/review all original and recurrence specimens with full histology, grade, and IHC; current primary/site remains unconfirmed.  \n\n- PET/CT is optional; obtain only if results would change palliative radiotherapy fields, systemic strategy, or clinical trial eligibility (no prior PET/CT).  \n\n- If PET/CT performed, integrate FDG findings with CT/MR to confirm bone (right iliac) and liver metastases for radiotherapy planning. [@2022-12-29|MR; @2022-12-29|CT]", "timestamp": "2026-01-18T17:39:28.194117"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver metastases, and new suspected iliac bone metastasis → non‑curative intent.\n- Severe anemia (Hgb 74 g/L) is a major constraint on systemic therapy; liver/renal function currently compatible with treatment if ECOG is acceptable.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic‑type malignancy.\n- HRD negative, BRCA1/2 wild type with ATM variant of uncertain significance → limited expected benefit from PARP; conventional systemic options or trials more relevant.\n\nControversies:\n- Unconfirmed primary site and histologic subtype (ovarian vs other gynecologic/pelvic origin); original stage unclear.\n- Systemic treatment intensity and feasibility cannot be decided safely without anemia work‑up, ECOG, and documented patient goals.\n- PET/CT considered optional in a clearly metastatic, non‑curative setting; potential role only if it would influence palliative radiotherapy planning, systemic strategy, or trial eligibility.\n\nMissing Info:\n- Pathology: original and recurrence reports with histology, grade, IHC, primary site confirmation, and staging; current decisions are being made without a fully confirmed histologic diagnosis.\n- Treatment history: prior systemic and radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences and goals of care.\n- Hematology: anemia etiology, iron/B12/folate status, hemolysis/bleeding assessment, transfusion history.\n- Updated labs/biomarkers: full biochemistry including eGFR, electrolytes, LFTs; somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline to map metabolic extent of visceral and bone disease.\n\nWorking Plan:\n- Reaffirm non‑curative, symptom‑focused intent and engage palliative care for pain and pelvic/visceral symptom control.\n- Urgently complete anemia work‑up and provide transfusion/supportive measures before any decision on systemic treatment intensity.\n- Formalize that systemic therapy intensity is deferred until anemia evaluation, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, and IHC to confirm primary/site.\n- Consider PET/CT only if results are needed to guide palliative radiotherapy targeting or to meet documentation requirements for clinical trials, with radiology–nuclear correlation for bone/liver lesions.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T17:39:43.079193"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver metastases, and new suspected iliac bone metastasis → non‑curative intent.\n- Severe anemia (Hgb 74 g/L) is a major constraint on systemic therapy; liver/renal function currently compatible with treatment if ECOG is acceptable.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic‑type malignancy.\n- HRD negative, BRCA1/2 wild type with ATM variant of uncertain significance → limited expected benefit from PARP; conventional systemic options or trials more relevant.\n\nControversies:\n- Unconfirmed primary site and histologic subtype (ovarian vs other gynecologic/pelvic origin); original stage unclear.\n- Systemic treatment intensity and feasibility cannot be decided safely without anemia work‑up, ECOG, and documented patient goals.\n- PET/CT considered optional in a clearly metastatic, non‑curative setting; potential role only if it would influence palliative radiotherapy planning, systemic strategy, or trial eligibility.\n\nMissing Info:\n- Pathology: original and recurrence reports with histology, grade, IHC, primary site confirmation, and staging; current decisions are being made without a fully confirmed histologic diagnosis.\n- Treatment history: prior systemic and radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences and goals of care.\n- Hematology: anemia etiology, iron/B12/folate status, hemolysis/bleeding assessment, transfusion history.\n- Updated labs/biomarkers: full biochemistry including eGFR, electrolytes, LFTs; somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline to map metabolic extent of visceral and bone disease.\n\nWorking Plan:\n- Reaffirm non‑curative, symptom‑focused intent and engage palliative care for pain and pelvic/visceral symptom control.\n- Urgently complete anemia work‑up and provide transfusion/supportive measures before any decision on systemic treatment intensity.\n- Formalize that systemic therapy intensity is deferred until anemia evaluation, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, and IHC to confirm primary/site.\n- Consider PET/CT only if results are needed to guide palliative radiotherapy targeting or to meet documentation requirements for clinical trials, with radiology–nuclear correlation for bone/liver lesions.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Non‑curative, symptom‑focused intent remains appropriate; engage palliative care for pelvic and visceral symptom management (clinical details currently unknown).  \n\n- Defer systemic treatment intensity until anemia work‑up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are documented.  \n\n- Pathology team to urgently retrieve/review all original and recurrence specimens with full histology, grade, IHC, and staging (currently unknown).  \n\n- PET/CT is optional; perform only if it will guide palliative radiotherapy targeting or clinical‑trial eligibility (no prior PET/CT available).  \n\n- If PET/CT obtained, correlate FDG‑avid bone and liver lesions with CT/MR to confirm metastases for radiotherapy planning. [@2022-12-29|MR; @2022-12-29|CT]", "timestamp": "2026-01-18T17:40:37.007159"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Advanced recurrent pelvic malignancy with progressive sacral, peritoneal, bone and liver metastases; intent should now be non-curative, symptom-focused. [@2022-12-29|MR; @2022-12-29|CT; @2022-10-24|CT]\\n\\n- Marked anemia (Hgb 74 g/L) requires urgent evaluation, transfusion consideration and cause clarification before systemic therapy decisions. [@20230103|5600862]\\n\\n- Liver and renal function currently acceptable, permitting consideration of further systemic therapy if performance status and symptoms allow. [@20221229|8300002]\\n\\n- Germline HRD-negative, BRCA wild type with ATM variant; PARP benefit uncertain, prioritize conventional systemic options or trials. [@OH2203828|2022-04-18]\\n\\n- Critical missing data: histology/grade, initial stage, prior treatments and responses, current ECOG, symptoms, and patient preferences/goals.\",\"oncologist\":\"- Tumor markers CA125, CA19-9, CA15-3 markedly elevated, supporting active gynecologic malignancy; histologic diagnosis and stage unknown/needs update. [@20221229|9703212]\\n\\n- Severe anemia (Hgb 74 g/L) likely limits intensity of cytotoxic therapy; etiology and transfusion/iron status unknown/needs update. [@20230103|5600862]\\n\\n- Renal and hepatic function acceptable for most systemic agents, but full panel including electrolytes and eGFR confirmation needed. [@20221229|8300002]\\n\\n- HRD negative, BRCA1/2 negative, germline ATM variant identified; implications for targeted therapy modest. [@OH2203828|2022-04-18]\\n\\n- Missing: exact cancer diagnosis, prior systemic treatments, treatment response, performance status, current disease burden/imaging to define line and intent.\",\"radiologist\":\"- Presacral pelvic mass enlarged to ~53×44 mm with more heterogeneous signal; involves adjacent peritoneum and sacrum, suggesting progressive local recurrence.[@2022-12-29|MR]\\n\\n- Persistent thickened vaginal stump and enhancing rectal wall segment adjacent to mass, raising concern for direct local involvement.[@2022-12-29|MR]\\n\\n- New enhancing nodule in right iliac bone, suspicious for osseous metastasis.[@2022-12-29|MR]\\n\\n- Multiple enhancing mesenteric/pelvic nodules unchanged, compatible with stable peritoneal metastatic disease.[@2022-12-29|MR]\\n\\n- Liver: multiple metastatic lesions increased in number and size; additional stable hepatic cysts and possible splenic infarct needing follow‑up.[@2022-12-29|CT]\",\"pathologist\":\"- No histology, grade, site, or IHC results are available; primary diagnosis cannot be confirmed or classified.  \\n- Germline ATM exon8 c.A947G:p.Y316C variant reported; clinical significance (pathogenic vs VUS) not specified. [@OH2203828|2022-04-18]  \\n- HRD testing reported negative; BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 pathogenic variants not detected. [@OH2203828|2022-04-18]  \\n- Tumor somatic NGS panel, MSI/MMR, TMB, and PD-L1 status unknown/needs update.  \\n- Full surgical pathology report (histotype, grade, stage, margins, residual disease) and IHC panel results unknown/needs update.\",\"nuclear\":\"- No prior PET/CT available; baseline metabolic characterization of pelvic, hepatic, and osseous lesions is unknown/needs PET-CT update.\\n\\n- MRI shows enlarging presacral mass with sacrum and peritoneal involvement, highly suspicious for local pelvic recurrence. [@2022-12-29|MR]\\n\\n- New right iliac bone enhancing lesion on MRI suggests possible osseous metastasis; PET could confirm metabolic activity and extent. [@2022-12-29|MR]\\n\\n- CT shows multiple increasing liver lesions consistent with metastases; PET may refine lesion count and confirm active disease burden. [@2022-12-29|CT]\\n\\n- PET/CT now would help refine staging (visceral and bone metastases vs localized recurrence) and guide future management planning.\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Progressive advanced pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, thickened vaginal stump/rectal involvement, stable peritoneal nodules, and increasing liver metastases; new suspected iliac bone metastasis → disseminated disease, non‑curative setting.\n- Marked anemia (Hgb 74 g/L) is a major limiting factor for any systemic therapy; liver and renal function currently acceptable for treatment if PS allows.\n- Tumor markers (CA125, CA19‑9, CA15‑3) markedly elevated, supporting active gynecologic-type malignancy.\n- Germline HRD negative, BRCA1/2 wild type, ATM variant (clinical impact uncertain); limited rationale for PARP, conventional systemic therapy or trials more relevant.\n\nControversies:\n- Exact primary site, histologic subtype, and stage not documented; uncertainty whether this is ovarian, endometrial, cervical, or other pelvic primary.\n- No consensus possible on further systemic therapy intensity without knowing anemia etiology, performance status, and patient goals.\n- Value/timing of further staging with PET/CT questioned in context of already clear metastatic, non‑curable disease versus its potential role in clarifying bone disease and overall burden.\n\nMissing Info:\n- Core oncology data: histology, grade, original stage, full surgical pathology, prior systemic/radiation treatments and responses.\n- Current clinical status: ECOG/PS, symptoms (pain, bleeding, bowel/bladder dysfunction, weight loss), and patient preferences/goals of care.\n- Hematology work‑up: cause of severe anemia, iron/B12/folate status, hemolysis, bleeding assessment; transfusion history.\n- Updated labs: full biochemistry including eGFR, electrolytes, LFTs; any tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT to define metabolic activity and full extent of osseous/visceral disease.\n\nWorking Plan:\n- Clarify intent as non‑curative, symptom‑focused; initiate/engage palliative care for pain, bowel/bladder, and pelvic symptom management.\n- Urgently investigate anemia and consider transfusion/supportive measures before any systemic treatment decisions.\n- Obtain missing oncologic history (pathology, prior lines, responses) and current ECOG/clinical status; discuss patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would realistically change systemic or local palliative strategies (e.g., radiotherapy to bone/pelvis, trial eligibility).\n- Defer specific treatment selection to treating team once above information and patient goals are defined.", "timestamp": "2026-01-18T17:38:17.437133"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Progressive advanced pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum, thickened vaginal stump/rectal involvement, stable peritoneal nodules, and increasing liver metastases; new suspected iliac bone metastasis → disseminated disease, non‑curative setting.\n- Marked anemia (Hgb 74 g/L) is a major limiting factor for any systemic therapy; liver and renal function currently acceptable for treatment if PS allows.\n- Tumor markers (CA125, CA19‑9, CA15‑3) markedly elevated, supporting active gynecologic-type malignancy.\n- Germline HRD negative, BRCA1/2 wild type, ATM variant (clinical impact uncertain); limited rationale for PARP, conventional systemic therapy or trials more relevant.\n\nControversies:\n- Exact primary site, histologic subtype, and stage not documented; uncertainty whether this is ovarian, endometrial, cervical, or other pelvic primary.\n- No consensus possible on further systemic therapy intensity without knowing anemia etiology, performance status, and patient goals.\n- Value/timing of further staging with PET/CT questioned in context of already clear metastatic, non‑curable disease versus its potential role in clarifying bone disease and overall burden.\n\nMissing Info:\n- Core oncology data: histology, grade, original stage, full surgical pathology, prior systemic/radiation treatments and responses.\n- Current clinical status: ECOG/PS, symptoms (pain, bleeding, bowel/bladder dysfunction, weight loss), and patient preferences/goals of care.\n- Hematology work‑up: cause of severe anemia, iron/B12/folate status, hemolysis, bleeding assessment; transfusion history.\n- Updated labs: full biochemistry including eGFR, electrolytes, LFTs; any tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT to define metabolic activity and full extent of osseous/visceral disease.\n\nWorking Plan:\n- Clarify intent as non‑curative, symptom‑focused; initiate/engage palliative care for pain, bowel/bladder, and pelvic symptom management.\n- Urgently investigate anemia and consider transfusion/supportive measures before any systemic treatment decisions.\n- Obtain missing oncologic history (pathology, prior lines, responses) and current ECOG/clinical status; discuss patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would realistically change systemic or local palliative strategies (e.g., radiotherapy to bone/pelvis, trial eligibility).\n- Defer specific treatment selection to treating team once above information and patient goals are defined.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.", "timestamp": "2026-01-18T17:38:22.315600"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver mets, and new suspected iliac bone metastasis → non‑curative context.\n- Severe anemia (Hgb 74 g/L) is a key constraint for systemic therapy; current liver/renal function could allow treatment if performance status is adequate.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic-type malignancy.\n- HRD negative, BRCA1/2 wild type; germline ATM variant of uncertain significance → limited expectation of PARP benefit, conventional systemic options/trials more relevant.\n\nControversies:\n- Primary site and histologic subtype not confirmed (ovarian vs other gynecologic/pelvic origin); stage at diagnosis unclear.\n- Feasibility/intensity of further systemic therapy uncertain without anemia work‑up, performance status, and patient goals.\n- Added value of PET/CT debated in clearly metastatic, non‑curative disease versus its potential role for defining bone involvement and total burden.\n\nMissing Info:\n- Pathology and treatment history: histology, grade, initial stage, surgical report, IHC, prior systemic/radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences/goals.\n- Hematology: cause of anemia, iron/B12/folate, hemolysis/bleeding assessment, transfusion history.\n- Updated labs and biomarkers: full biochemistry with eGFR/electrolytes, LFTs; tumor somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline for metabolic assessment of visceral/bone disease.\n\nWorking Plan:\n- Confirm non‑curative, symptom‑focused intent and involve palliative care for pain and pelvic/visceral symptom management.\n- Urgently investigate anemia etiology and provide appropriate transfusion/supportive care before systemic therapy decisions.\n- Retrieve full oncologic history and pathology; document current ECOG and symptoms; elicit patient priorities and acceptable toxicity.\n- Consider PET/CT only if results would change palliative radiotherapy plans, systemic approach, or trial eligibility.\n- Leave specific regimen/therapy choices to the treating team once missing data and goals of care are clarified.\n[R1T1 DELTA] influence palliative radiotherapy planning, systemic strategy, or clinical trial eligibility in this clearly metastatic, non-curative setting. | oncologist->chair(safety): Given severe anemia and unclear performance status, I’d hold systemic-intensity decisions until anemia work-up, ECOG, and patient goals are documented. | oncologist->nuclear(missing): PET/CT seems optional in this clearly metastatic, non-curative setting unless needed to plan palliative radiotherapy or trial eligibility. | pathologist->oncologist(missing): Primary site and histologic subtype remain unconfirmed; obtaining original surgical pathology with full histology, grade, and IHC is critical for accurate classification. | pathologist->chair(missing): Key diagnostic pathology (initial report, IHC, and any re-biopsy of recurrent sites) is missing; MDT decisions are being made without a confirmed histologic diagnosis.\n[R1T2 DELTA] oncologist(safety): Please formalize that systemic treatment intensity is deferred until anemia work-up, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented. | chair->pathologist(missing): Kindly prioritize retrieval/review of all original and recurrence pathology with full histology, grade, and IHC so that ongoing management is not based on an unconfirmed primary/site. | nuclear->oncologist(missing): From a nuclear perspective, PET/CT is optional but could meaningfully refine bone and whole‑body disease mapping if you’re considering targeted palliative radiotherapy or trial screening that requires precise metastatic documentation. | nuclear->radiologist(missing): If PET/CT is obtained, please correlate FDG‑avid bone and liver lesions with prior CT/MR to distinguish metastases from benign/incidental findings for radiotherapy planning.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Disseminated recurrent pelvic malignancy with presacral mass invading sacrum/peritoneum, probable vaginal stump/rectal involvement, stable peritoneal disease, progressive liver metastases, and new suspected iliac bone metastasis → non‑curative intent.\n- Severe anemia (Hgb 74 g/L) is a major constraint on systemic therapy; liver/renal function currently compatible with treatment if ECOG is acceptable.\n- Markedly elevated CA125, CA19‑9, CA15‑3 support an active gynecologic‑type malignancy.\n- HRD negative, BRCA1/2 wild type with ATM variant of uncertain significance → limited expected benefit from PARP; conventional systemic options or trials more relevant.\n\nControversies:\n- Unconfirmed primary site and histologic subtype (ovarian vs other gynecologic/pelvic origin); original stage unclear.\n- Systemic treatment intensity and feasibility cannot be decided safely without anemia work‑up, ECOG, and documented patient goals.\n- PET/CT considered optional in a clearly metastatic, non‑curative setting; potential role only if it would influence palliative radiotherapy planning, systemic strategy, or trial eligibility.\n\nMissing Info:\n- Pathology: original and recurrence reports with histology, grade, IHC, primary site confirmation, and staging; current decisions are being made without a fully confirmed histologic diagnosis.\n- Treatment history: prior systemic and radiation therapies and responses.\n- Current clinical status: ECOG PS, symptom burden (pain, bleeding, bowel/bladder issues, weight loss), patient preferences and goals of care.\n- Hematology: anemia etiology, iron/B12/folate status, hemolysis/bleeding assessment, transfusion history.\n- Updated labs/biomarkers: full biochemistry including eGFR, electrolytes, LFTs; somatic NGS, MSI/MMR, TMB, PD‑L1.\n- Imaging: no PET/CT baseline to map metabolic extent of visceral and bone disease.\n\nWorking Plan:\n- Reaffirm non‑curative, symptom‑focused intent and engage palliative care for pain and pelvic/visceral symptom control.\n- Urgently complete anemia work‑up and provide transfusion/supportive measures before any decision on systemic treatment intensity.\n- Formalize that systemic therapy intensity is deferred until anemia evaluation, ECOG, patient goals, and foundational pathology (histology/IHC, primary site) are obtained and documented.\n- Pathology team to prioritize retrieval/review of all original and recurrence specimens with full histology, grade, and IHC to confirm primary/site.\n- Consider PET/CT only if results are needed to guide palliative radiotherapy targeting or to meet documentation requirements for clinical trials, with radiology–nuclear correlation for bone/liver lesions.", "timestamp": "2026-01-18T17:39:33.544835"}]}, "trace_events": [{"ts": "2026-01-18T17:37:22.097186", "event": "pipeline_start", "payload": {"visit_time": "2023-01-03 08:53:29.260000", "meta_info": "340123197709263626"}}, {"ts": "2026-01-18T17:37:22.097378", "event": "case_fingerprint", "payload": {"case_fingerprint": "bf21a9e8fbc5"}}, {"ts": "2026-01-18T17:37:22.364557", "event": "reports_loaded", "payload": {"lab_n": 92, "img_n": 10, "path_n": 0, "mut_n": 1, "cutoff_dt": "2023-01-04 08:53:29"}}, {"ts": "2026-01-18T17:37:33.946685", "event": "reports_selected", "payload": {"lab": {"chair": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "oncologist": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": ["2022-10-24|CT|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "oncologist": [], "radiologist": ["2022-10-24|MR|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "pathologist": [], "nuclear": ["2022-10-24|CT|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"]}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": ["OH2203828|2022-04-18"], "oncologist": ["OH2203828|2022-04-18"], "radiologist": [], "pathologist": ["OH2203828|2022-04-18"], "nuclear": []}}}, {"ts": "2026-01-18T17:37:50.761170", "event": "rag_query", "payload": {"query": "Recurrent platinum-unknown ovarian cancer with peritoneal carcinomatosis and ascites, unknown BRCA/HRD status, good performance status and no major organ dysfunction: evidence-based options for systemic therapy, role of surgery, targeted agents, or maintenance strategies."}}, {"ts": "2026-01-18T17:37:50.761200", "event": "rag_hits", "payload": {"source": "guideline", "topk": 5, "n": 5}}, {"ts": "2026-01-18T17:37:50.761206", "event": "rag_hits", "payload": {"source": "pubmed", "topk": 5, "n": 5}}, {"ts": "2026-01-18T17:37:50.761211", "event": "rag_hits_merged", "payload": {"n": 10}}, {"ts": "2026-01-18T17:37:58.507107", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-18T17:40:37.007244", "event": "mdt_discussion_end", "payload": {"merged_chars": 2685}}, {"ts": "2026-01-18T17:40:37.007956", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-18T17:40:40.601252", "event": "final_output_end", "payload": {"final_output_chars": 1262}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Guideline+PubMed RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
